Migraine - Current understanding and treatment

New England Journal of Medicine

Volumn 346, Issue 4, 2002, Pages 257-270

  Goadsby, Peter J ^a,e   Lipton, Richard B ^b,c   Ferrari, Michel D ^d  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Innovative Medical Research   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DONITRIPTAN; ELETRIPTAN; ERGOT DERIVATIVE; FLUNARIZINE; FROVATRIPTAN; GABAPENTIN; IBUPROFEN; METHYSERGIDE; METOPROLOL; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PIZOTIFEN; PROPRANOLOL; RIZATRIPTAN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL; ZOLMITRIPTAN;

CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; PAIN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TREMOR; WEIGHT GAIN;

ANALGESICS; ERGOTAMINES; HUMANS; MIGRAINE DISORDERS; PAIN; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

EID: 0037165257     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra010917     Document Type: Review

References (144)

1. Migraine diagnosis and treatment: Results from the American Migraine Study II
2. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
3. Diagnosis and management of migraine
4. Headache and face pain
5. Migraine with aura and migraine without aura: An epidemiological study
6. The prevalence and characteristics of migraine in a population-based cohort: The GEM study
7. Reliability of the Migraine Disability Assessment score in a population- based sample of headache sufferers
8. Prevalence of migraine headache in the United States: Relation to age, income, race and other sociodemographic factors
9. Symptomatic and nonsymptomatic headaches in a general population
10. Epidemiology of migraine in England
11. Burden of migraine: Societal costs and therapeutic opportunities
12. The global burden of disease study: Implications for neurology
13. Pathophysiology of headache
14. The trigeminovascular system in humans: Pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation
15. 2- channel gene CACNL1A4
16. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura
17. Migraine, aura, and cortical spreading depression: Why are we still talking about it?
18. Brain stem activation in spontaneous human migraine attacks
19. Brainstem activation specific to migraine headache
20. Spreading depression of activity in the cerebral cortex
21. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine
22. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache
23. Perfusion weighted imaging during migraine: Spontaneous visual aura and headache
24. Perfusion-weighted imaging defects during spontaneous migrainous aura
25. Pathophysiology of the migraine aura: The spreading depression theory
26. Mechanisms of migraine aura revealed by functional MRI in human visual cortex
27. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks
28. Functional MRIBOLD of visually triggered headache in patients with migraine
29. An association between migraine and cutaneous allodynia
30. Innervation of intracranial structures: A reappraisal
31. Headaches during intracranial endovascular procedures: A possible model of vascular headache
32. Focal headache during balloon inflation in the vertebral and basilar arteries
33. The sensory distribution of the fifth cranial nerve
34. Dural headache and innervation of the dura mater
35. The tentorial nerves and local ization of intracranial pain in man
36. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat
37. Stimulation of the middle meningeal artery leads to bilateral Fos expression in the trigeminocervical nucleus: A comparative study of monkey and cat
38. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: A c-fos immunocytochemical study
39. A mechanism to account for frontal headache in cases of posterior-fossa tumors
40. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat
41. Stimulation of the greater occipital nerve (GON) enhances responses of dural responsive convergent neurons in the trigemino-cervical complex in the rat
42. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
43. Sumatriptan: A receptor-targeted treatment for migraine
44. Retinal plasma extravasation in animals but not in humans: Implications for the pathophysiology of migraine
45. Magnetic resonance angiography in facial and other pain: Neurovascular mechanisms of trigeminal sensation
46. Multispecialty consensus on diagnosis and treatment of headache
47. Drug therapy of migraine
48. 2000 Wolfe Award: Sumatriptan for the range of headaches in migraine sufferers: Results of the Spectrum Study
49. Atypical facial pain: A double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan
50. Monitoring of acute migraine attacks: Placebo response and safety data
51. Efficacy of gabapentin in migraine prophylaxis
52. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine
53. Fibrotic disorders associated with methysergide therapy for headache
54. Cardiac and pulmonary fibrosis during methysergide therapy for headache
55. Divalproex sodium in headache: Literature review and clinical guidelines
56. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
57. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine
58. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A double-blind study
59. Efficacy and safety of acetaminophen in the nonprescription treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study
60. Naproxen sodium in the treatment of migraine
61. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study
62. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials
63. Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: Results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine
64. Absorption of effervescent aspirin during migraine
65. A combination ofibuprofen lysine (IBL) and domperidone maleate (DOM) in the acute treatment of migraine: A double-blind study
66. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement): Report of the Quality Standards Subcommittee of the American Academy of Neurology
67. Ergotamine in the acute treatment of migraine: A review and European consensus
68. Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
69. Pharmacokinetic and metabolic data on almotriptan, A new antimigraine drug
70. Pharmacokinetics of oral almotriptan during and outside a migraine attack
71. 1D-like" receptor partial agonist
72. Comparative absorption and elimination of eletriptan in rat, dog and human
73. Frovatriptan pharmacokinetics are unaffected during a migraine attack
74. Pharmacokinetics of frovatriptan (VML251/SB 209509) in healthy young and elderly male and female subjects
75. Oral naratriptan tablets (2.5-10 mg) exhibit dose-proportional pharmacokinetics
76. A study to determine the absolute oral bioavailability of naratriptan
77. ID agonist
78. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers
79. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers
80. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-lD agonist: A comparison of its absorption during a migraine attack and in a migraine-free period
81. Zolmitriptan
82. Tolerability of sumatriptan: Clinical trials and post-marketing experience
83. Serotonin and migraine
84. Biochemical investigations in headache: Increase in hydroxyindoleacetic acid excretion during migraine attacks
85. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects
86. Plasma serotonin in migraine and stress
87. Effect of serotonin in migraine patients
88. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome
89. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head
90. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs
91. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
92. Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes
93. 1F) receptor agonist LY334370 for acute migraine: A randomised controlled trial
94. 1D-selective ligands)
95. 1D agonist, in patients with acute migraine
96. Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633E
97. The pharmacology of headache
98. The mode of action of sumatriptan is vascular? A debate
99. 1B/1D agonist: Key features and acute antimigraine potential
100. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?
101. Treatment of migraine attacks with sumatriptan
102. Sumatriptan suppositories for the acute treatment of migraine
103. Sumatriptan nasal spray in the acute treatment of migraine: A review of clinical studies
104. Coronary side-effect potential of current and prospective antimigraine drugs
105. Development and characterisation of human 5-HT1B- or 5HT1D-receptor specific antibodies as unique research tools
106. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs
107. Methodology of clinical trials of sumatriptan in migraine and cluster headache
108. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials
109. 1B/1D agonists) in migraine: Methods and detailed results of a metaanalysis of 53 trials
110. Using numerical results from systematic reviews in clinical practice
111. Guidelines for controlled trials of drugs in migraine: Second edition
112. A placebo-controlled crossover study of tizatriptan in the treatment of multiple migraine attacks
113. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
114. Sumatriptan in clinical practice: A 2-year review of 453 migraine patients
115. Treatment of migraine attacks with subcutaneous sumatriptan: First placebo-controlled study
116. Treatment of acute cluster headache with sumatriptan
117. Intranasal sumatriptan for the acute treatment of migraine in children
118. Sumatriptan nasal spray in the acute treatment of migraine in adolescent migraineurs
119. The tolerability, safety and efficacy of oral sumatriptan 50mmg and 100mg for the acute treatment of migraine in adolescents
120. Efficacy and safety of naratriptan tablets in adolescent migraine
121. Clinical utility of a new instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) score
122. Stratified care vs step care strategies for migraine: The Disability in Strategies of Care (DISC) Study: A randomized trial
123. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
124. Substance-P antagonist RPR 100893-201 is not effective in human migraine attacks
125. Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study
126. Lanepitant, an NK-1 antagonist, in migraine prevention
127. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine
128. 1, receptor antagonist in the acute treatment of migraine
129. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks
130. A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females
131. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials
132. Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine
133. IV LY293558, an AMPA/KA receptor antagonist, is effective in migraine
134. Inhibitory effects of adenosine A1 agonists on the cat trigeminovascular system: A new target for anti-migraine drugs?
135. 1 receptor activation: A novel approach towards the design of new anti-migraine compounds
136. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
137. Nitric oxide synthase inhibition in migraine
138. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study
139. 2+ channel defects in migraine, ataxia and epilepsy